HALO: Halozyme Therapeutics, Inc. Kompaniya qiymatining sof foydaga nisbati

Halozyme Therapeutics, Inc. - HALO emitenti grafik logotipi

Yengib bo'lmas patent to'siqlari va qimmatbaho sinovlar Halozyme Therapeutics (HALO) uchun dori yetkazib berish nishasiga kirishni deyarli imkonsiz qiladi. Joriy P/E koeffitsiyenti ushbu barqarorlikni aks ettiradi va uning hozirgi qiymati 22.40 ga tengdir. Biznes asosi sog'liqni saqlash gigantlariga texnologiyalarni litsenziyalashga asoslangan, royalti yig'ish modeli esa minimal operatsion xarajatlar bilan tezkor foyda o'sishini ta'minlaydi.

Narx-foyda koeffitsiyenti: Halozyme Therapeutics (HALO) 04.07.2022 - 17.11.2026 uchun

Halozyme Therapeutics, Inc. (HALO) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- aksiya kursi va ekspertlarning narx prognozi:
- bozor kapitallashuvi haqida ma'lumot:
Kompaniyaning jamlanma tahlili:Halozyme - HALO
Halozyme yetakchi tovari

Halozyme Therapeutics (HALO) biotexnologiya litsenziyalashining no-tsiklik tabiati makroiqtisodiy zarbalardan qat'i nazar, barqaror royalti oqimini kafolatlaydi. Bozor kapitalizatsiyasining sof foydaga nisbati ushbu barqaror daromadning qiymatini matematik jihatdan aks ettiradi. Ushbu koeffitsient investitsiya samaradorligini va tashqi omillarning emitentning real rentabelligiga ta'sirini o'lchaydi. Kompaniyaga tegishli o'rtacha P/E tendentsiyasi bozorning biznesni tan olishini baholash va aktiv uchun haddan tashqari ko'p to'lov qilish bilan bog'liq xavflarni o'z vaqtida aniqlash imkonini beradi.

Muhim raqobatchilar

ONC: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti RVMD (RevMed)|AAPG (Ascentage) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori CGON (cgoncology.com)|URGN - Narx-foyda koeffitsiyenti|BCAX: Narx-foyda koeffitsiyenti|PSNL - P/E multiplikatori|Erasca Corp (ERAS) - Narxning foydaga nisbati|Delcath - Kompaniya qiymatining sof foydaga nisbati|YMAB (Y-mAbs Therapeutics Inc) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Aura Biosciences, Inc. AURA|P/E multiplikatori CADL|P/E multiplikatori Accuray (ARAY)|Narxning foydaga nisbati SELLAS Life Sciences Group Inc. SLS|ACTU - Narx-foyda koeffitsiyenti|CTOR: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati HURA (TuHURA Biosciences Inc.)|TARA (Protara Therapeutics) - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning foydaga nisbati Fate Therapeutics Corp (FATE)|Narx-foyda koeffitsiyenti WHWK|Narx-foyda multiplikatori TCRX (TScan Therapeutics, Inc.)|P/E multiplikatori CSBR|XBIT - Kapitalizatsiyaning foydaga nisbati|CEL-SCI Corporation - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati OSTX|radiopharmtheranostics.com - P/E multiplikatori|ARTV: Narxning foydaga nisbati|ANL (adlainortye.com) - Narx-foyda koeffitsiyenti|VERU - Biznesning o‘zini qoplash muddati|TPST (Tempest Therapeutics, Inc.) - P/E multiplikatori|P/E multiplikatori xiliotx.com|Narxning foydaga nisbati Enochian BioSciences (RENB)|Narxning foydaga nisbati MURA (Mural Oncology PLC)|Narxning foydaga nisbati Kairos Pharma Ltd KAPA|P/E multiplikatori OnKure Therapeutics Inc OKUR|CytoMed Therapeutics - P/E multiplikatori|Biznesning o‘zini qoplash muddati Curis CRIS|APLM: P/E multiplikatori|Narx-foyda koeffitsiyenti Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E multiplikatori|Genprex - Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Kapitalizatsiyaning foydaga nisbati|PPBT: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Narxning foydaga nisbati|Checkpoint Therapeutics, Inc (CKPT) - P/E multiplikatori|Narxning foydaga nisbati Elevation Oncology, Inc.|ICAD: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati ikenaoncology.com (IKNA)|Narxning foydaga nisbati NTBL (Notable Labs, Ltd.)|P/E multiplikatori VIRX (viracta.com)|MOR - Narx-foyda koeffitsiyenti|NAYA - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati AAPGV